News

Using Standard Digoxin Nomogram Can Lead to Deadly Overdoses


 

MUNICH — Patients with heart failure who are treated with digoxin administered according to the standard nomogram risk getting an overdose that might kill them.

“We recommend treating patients who get digoxin with half the dose from the nomogram,” said Kirkwood F. Adams Jr., M.D., at the annual congress of the European Society of Cardiology.

Half the standard dosage will give most patients a serum level of 0.5-0.9 ng/mL. A post hoc analysis of data collected in the landmark Digitalis Investigation Group (DIG) trial, run during the early 1990s, showed that patients who have a serum level in this range had a 15%-20% reduced risk of death during follow-up compared with patients who did not receive digoxin, reported Dr. Adams, a cardiologist at the University of North Carolina in Chapel Hill.

In contrast, patients who had serum levels of 1.2-1.5 ng/mL had a death rate that was 33% higher than that of matched placebo patients. This risk is believed to be due to the neurohormonal effects of a relatively high serum level of the drug. At lower serum levels, digoxin probably has a small inotropic effect that is safe and beneficial, Dr. Adams told this newspaper.

The DIG trial, which began enrolling patients in 1991, was completed in December, 1995; the primary results were reported in 1997. The 6,800 patients with stable heart failure were randomized to treatment with digoxin or placebo on top of what was standard heart failure treatment at that time. The primary finding of the study was that digoxin treatment had no effect on mortality compared with placebo, but it did reduce the hospitalization rate (N. Engl. J. Med. 1997;336:525-33).

The post hoc analysis by Dr. Adams and his associates focused on the 1,843 patients in the digoxin arm of the study who had their serum concentration of the drug checked after they had been on treatment for 4 weeks, an indicator of their steady-state level of the drug

The relationship between serum levels of digoxin after 4 weeks of treatment and mortality was similar in men and women.

The standard nomogram for calculating a digoxin dosage dates to 1974 and takes into account a patient's body mass index and renal function. But there can be substantial variability in the actual serum level that individual patients maintain from a particular dosage. Using the nomogram, most patients receive a dosage of 0.25 mg/day. A better dosage based on these findings would be 0.125 mg/day, Dr. Adams said.

All patients with heart failure who receive digoxin should have their serum level checked after 4 weeks and then have their dosage modified if the level is outside of the 0.5-0.9 ng/mL range, he added.

Recommended Reading

TNT Trial Shows Lower Is Better in Treating High Cholesterol
MDedge Family Medicine
Study Tracks Endothelial Function in Kawasaki
MDedge Family Medicine
Long-Term Study of Kawasaki Targets Risk of Atherosclerosis
MDedge Family Medicine
Study Assesses Interaction Between Warfarin, Antibiotics in Children
MDedge Family Medicine
Cardiac Abnormalities May Appear Late in KD Patients
MDedge Family Medicine
Incidence of Kawasaki Disease Holding Steady
MDedge Family Medicine
Kawasaki Disease Doesn't Reduce Quality of Life
MDedge Family Medicine
Drug-Eluting Stent Uses Rapidly Proliferating
MDedge Family Medicine
Lower Heart Risk After Breast Ca Radiation
MDedge Family Medicine
High-Risk Patients Should Receive Coronary Calcium Screening
MDedge Family Medicine